Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Summary

Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer. This study is conducted to evaluate the efficacy and safety of nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local advanced inoperable squamous cell lung cancer.

Timeline

Start

2019-03-20

Primary completion

2021-12-12

Completion

2021-12-12

Outcome

Outcome not reported

Stopped (Enrollment): “The study was halted because enrollment was too slow”

Drugs

Indications